RESPONSE OF RAT MODEL OF PNEUMOCYSTIS-CARINII PNEUMONIA TO CONTINUOUS-INFUSION OF DEFEROXAMINE

被引：20

作者：

MERALI, S

CHIN, K

GRADY, RW

WEISSBERGER, L

CLARKSON, AB

机构：

[1] NYU,SCH MED,DEPT MED & MOLEC PARASITOL,NEW YORK,NY 10016

[2] CORNELL UNIV,COLL MED,DEPT PEDIAT,NEW YORK,NY 10021

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1995年 / 39卷 / 07期

关键词：

D O I：

10.1128/AAC.39.7.1442

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The iron-chelating drug deferoxamine mesylate (DFO) is active against Pneumocystis carinii in vitro and in rat and mouse models of P. carinii pneumonia. Because DFO has a short half-life, daily divided or continuous dosage was expected to improve the dose response, as is the case with DFO treatment of malaria. Therefore, results of single daily intraperitoneal injections were compared with results of an evenly divided four-times-daily dosage and the efficacy of delivery with implanted infusion pumps. The highest bolus dosage (1,000 mg kg(-1) of body weight day(-1)) was as effective as the standard combination of trimethoprim with sulfamethoxazole. Unexpectedly, very little improvement was observed with the divided or continuous dosage, and several mechanisms that could account for this are discussed.

引用

页码：1442 / 1444

页数：3

共 18 条

[1] PHARMACOKINETICS AND RENAL ELIMINATION OF DESFERRIOXAMINE AND FERRIOXAMINE IN HEALTHY-SUBJECTS AND PATIENTS WITH HEMOCHROMATOSIS
ALLAIN, P
MAURAS, Y
CHALEIL, D
SIMON, P
ANG, KS
CAM, G
LEMIGNON, L
SIMON, M
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 24 (02) : 207 - 212
[2] ALLAIN P, 1987, CLIN CHIM ACTA, V170, P3331
[3] CHANG TMS, 1983, LANCET, V2, P1051
[4] DEFEROXAMINE AND EFLORNITHINE (DL-ALPHA-DIFLUOROMETHYLORNITHINE) IN A RAT MODEL OF PNEUMOCYSTIS-CARINII PNEUMONIA
CLARKSON, AB
SARIC, M
GRADY, RW
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (09) : 1833 - 1835
[5] RECENT ADVANCES IN THE DIAGNOSIS, TREATMENT, AND PREVENTION OF PNEUMOCYSTIS-CARINII PNEUMONIA
DAVEY, RT
MASUR, H
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (04) : 499 - 504
[6] Fleiss J. L., 1986, RELIABILITY MEASUREM
[7] GORDEUK VR, 1994, PROGR IRON RES, P371
[8] ADVANTAGES OF A MODIFIED TOLUIDINE BLUE-O STAIN AND BRONCHOALVEOLAR LAVAGE FOR THE DIAGNOSIS OF PNEUMOCYSTIS-CARINII PNEUMONIA
GOSEY, LL
HOWARD, RM
WITEBSKY, FG
OGNIBENE, FP
WU, TC
GILL, VJ
MACLOWRY, JD
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1985, 22 (05) : 803 - 807
[9] PNEUMOCYSTIS-CARINII PNEUMONIA - A COMPARISON BETWEEN PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME AND PATIENTS WITH OTHER IMMUNODEFICIENCIES
KOVACS, JA
HIEMENZ, JW
MACHER, AM
STOVER, D
MURRAY, HW
SHELHAMER, J
LANE, HC
URMACHER, C
HONIG, C
LONGO, DL
PARKER, MM
NATANSON, C
PARRILLO, JE
FAUCI, AS
PIZZO, PA
MASUR, H
[J]. ANNALS OF INTERNAL MEDICINE, 1984, 100 (05) : 663 - 671
[10] LEE P, 1993, DRUG METAB DISPOS, V21, P640

← 1 2 →